Navigation Links
72% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds
Date:5/13/2008

Foamix Offers New Intravaginal Foam Technology with Improved Usability &

Compliance

NESS ZIONA, Israel, May 13 /PRNewswire/ -- Despite the high incidence of women's health conditions that require intra-vaginal drug delivery and the abundance of intravaginal creams, gels and ovules, a recent survey found that an alarming majority of women find their current treatment options "unacceptable" or "intolerable". The survey, conducted by Elixir-Applied Researches for Foamix, polled more than 200 women.

Findings show that the majority of females who have used intravaginal drugs find them dissatisfying because these products leak out of the vagina following treatment (72%), because of irritation, itch or bad smell (60%), or simply because they are inconvenient to use (58%). 82% of the panellists opined that they would trade their current medication for a new form that does not leak; and 65% would prefer a product that does not cause irritation, itch or bad smell.

Foamix develops foam delivery systems for intravaginal administration that expand gently in the vaginal cavity and evenly cover the entire vaginal surface for efficient treatment. The Foamix foams are administered in small and accurate amounts, (using metered dose valves). They are bioadhesive to reduce dosing frequency and are constituted of non-irritating ingredients. Notably, the Foamix foams are fully retained inside the vagina, resulting in non leakage and enhanced efficacy.

"It seems the majority of women are dissatisfied with the current intravaginal treatment options. Treatment inconvenience is known to result in poor treatment compliance and there is therefore still a need for new drug delivery systems that can be easily administered, enable adherence of drugs to the vaginal surface and do not leak out or cause irritation," says Arie Yeshaya, M.D., Senior Gynecologist at Rabin Medical Center, Israel (affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel); and a women's health consultant to Foamix.

"The Foamix foam concept hits right on the spot of the drawbacks of current treatments," he adds.

"The Foamix intravaginal foam platform was developed with these difficulties in mind. We are working with major pharma companies to co-develop and market new intravaginal and dermal foam formulations," says Dr. Dov Tamarkin, CEO of Foamix Ltd.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix is currently collaborating with 10 pharmaceutical companies on 11 projects in the development of proprietary dermal and intravaginal drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation. Foamix holds 4 US patents and has 64 US patents pending, with further filings worldwide.

For additional information please visit http://www.foamix.co.il

Press inquiries:

Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
3. KGI and Smith College Establish Leadership Forum for Women in Bioscience
4. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
5. ABCs Private Practice Inaccurately Portrays Serious Womens Health Condition
6. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
7. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
8. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
9. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
10. Collaboration Sparks Creation of New Grand Rapids Laboratory Focused on Womens Health
11. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):